BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 11957790)

  • 1. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with ursodeoxycholic acid in cholestatic liver disease.
    Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
    Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bile acids in liver diseases--current indications].
    Stiehl A
    Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of autoimmune hepatic diseases].
    Bueverov AO
    Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid therapy in hepatobiliary disease.
    Kowdley KV
    Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of cholestatic liver diseases.
    Paumgartner G
    J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 17. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis.
    de Caestecker JS
    Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):145-7. PubMed ID: 9058624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.